Hyaluronic Acid Delivery: CO2 Laser Versus Thulium Laser Treatment
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · May 26, 2024
Trial Information
Current as of February 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two types of laser treatments—CO2 laser and thulium laser—to see how well they help deliver a substance called hyaluronic acid (HA) into the skin. HA is often used to improve skin quality, especially for aging skin, but the usual method of injecting it can cause bumps for a few days. By using lasers first, the researchers want to find out how the skin changes at the microscopic level after HA is applied, which could lead to better results and fewer side effects.
To participate in this trial, you need to be a healthy adult between the ages of 65 and 74, and both men and women are welcome. However, if you are pregnant, breastfeeding, or have any open wounds in the area being treated, you won't be able to join. If you decide to participate, you can expect to receive one of the laser treatments followed by the HA application, and the study aims to explore how these methods work together to improve skin quality. This could be an exciting opportunity to contribute to research that may benefit others with similar skin concerns in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - healthy male and female patients
- Exclusion Criteria:
- • pregnancy, breast feeding
- • open wounds at the area to be treated
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0